started · updated
Molecular Designs receives FDA clearance for respiratory virus panel
Molecular Designs has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SimplicityDx Panel FluA/FluB/RSV. This marks the company’s first FDA-cleared assay.
The multiplex real-time RT-PCR test is designed to qualitatively detect and differentiate influenza A, influenza B, and respiratory syncytial virus (RSV) RNA using anterior nasal swab specimens. The test aims to assist in differential diagnosis for individuals exhibiting respiratory tract infection symptoms.
The panel features a breakaway format intended to allow laboratories to use only the specific tests required for a given run, which may help reduce waste and simplify inventory management. It is designed to work in conjunction with the company’s Simplicity Dx Extraction products and supports batch processing for high-volume periods.
Entities
Michael Clark · Molecular Designs · U.S. Food and Drug Administration